StreetInsider.com News Articles

10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026

Wed, 15 Jul 2026 16:05:00 -0400

PLEASANTON, Calif., July 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the second quarter ended June 30, 2026 after market close on Thursday, August 6, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will

10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026

Wed, 15 Jul 2026 16:05:00 -0400

10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026

Wed, 15 Jul 2026 16:05:00 -0400

10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026

Wed, 15 Jul 2026 16:05:00 -0400

10X Genomics (TXG) PT Raised to $50 at Canaccord

Tue, 14 Jul 2026 06:42:34 -0400

Canaccord analyst Kyle Mikson raised the price target on 10X Genomics (NASDAQ: TXG) to $50.00 (from $32.00) while maintaining a Buy rating.

10X Genomics (TXG) PT Raised to $37 at Morgan Stanley

Thu, 09 Jul 2026 08:15:33 -0400

Morgan Stanley analyst Kallum Titchmarsh raised the price target on 10X Genomics (NASDAQ: TXG) to $37.00 (from $22.00) while maintaining a Equalweight rating.

10X Genomics (TXG) PT Raised to $45 at Citi

Wed, 08 Jul 2026 05:47:19 -0400

Citi analyst Patrick Donnelly raised the price target on 10X Genomics (NASDAQ: TXG) to $45.00 (from $24.00) while maintaining a Neutral rating.

10X Genomics (TXG) PT Raised to $42 at Piper Sandler

Wed, 01 Jul 2026 08:39:19 -0400

(Updated - July 1, 2026 8:39 AM EDT)

Piper Sandler analyst David Westenberg raised the price target on 10X Genomics (NASDAQ: TXG) to $42.00 (from $20.00) while maintaining a Neutral rating.

The analyst commented: "We believe 10x Genomics is a compelling name in multiomics due to their dominant position in single-cell RNA sequencing and spatial biology. Their Chromium and Xenium platforms have become the industry standard for biopharma translational research, providing the high-resolution biological context that is increasingly required for drug discovery and patient stratification. With the June 2026 integration of high-plex protein detection into their spatial workflows, we believe 10x is

10X Genomics (TXG) PT Raised to $42 at Piper Sandler

Wed, 01 Jul 2026 08:39:19 -0400

(Updated - July 1, 2026 8:39 AM EDT)

Piper Sandler analyst David Westenberg raised the price target on 10X Genomics (NASDAQ: TXG) to $42.00 (from $20.00) while maintaining a Neutral rating.

Form 4 10x Genomics, Inc. For: Jun 22 Filed by: Saxonov Serge

Wed, 24 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260624/26685834.html

Form 4 10x Genomics, Inc. For: Jun 22 Filed by: Saxonov Serge

Wed, 24 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260624/26685834.html

10X Genomics (TXG) PT Raised to $40 at Barclays

Wed, 24 Jun 2026 02:58:47 -0400

Barclays analyst Luke Sergott raised the price target on 10X Genomics (NASDAQ: TXG) to $40.00 (from $30.00) while maintaining a Overweight rating.

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist